Literature DB >> 3109993

Effect of workup strategy on the cost-effectiveness of fecal occult blood screening for colorectal cancer.

M J Barry, A G Mulley, J M Richter.   

Abstract

Physicians respond to a positive fecal occult blood test with a variety of workup strategies. To study the effect of the choice of strategy on the net costs and health benefits of colorectal cancer screening using this test, we used a decision analysis model to compare seven strategies that physicians might choose to examine a positive "screenee." Strategies using rigid or flexible sigmoidoscopy alone are not only insensitive, but also have high cost-effectiveness ratios. The strategy of air contrast barium enema alone had the lowest cost-effectiveness ratio. Rigid sigmoidoscopy combined with barium enema had a lower cost-effectiveness ratio than primary colonoscopy, but the strategy of primary colonoscopy could have an equal or better ratio depending on assumptions about test costs and the benefit of removing benign polyps. The primary colonoscopy strategy is both more effective and less costly than the combination of flexible sigmoidoscopy and barium enema. The optimal strategy will vary with local factors, and with the perspective of the decision-maker.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3109993     DOI: 10.1016/0016-5085(87)91019-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  7 in total

Review 1.  The limited incorporation of economic analyses in clinical practice guidelines.

Authors:  Joel F Wallace; Scott R Weingarten; Chiun-Fang Chiou; James M Henning; Andriana A Hohlbauch; Margaret S Richards; Nicole S Herzog; Lior S Lewensztain; Joshua J Ofman
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

2.  Comparison between double-contrast barium enema and colonoscopy to investigate lower gastrointestinal bleeding.

Authors:  E Jaramillo; P Slezak
Journal:  Gastrointest Radiol       Date:  1992

Review 3.  Cost-effective management of colon and rectal cancer.

Authors:  J A Heine; D A Rothenberger
Journal:  World J Surg       Date:  1991 Sep-Oct       Impact factor: 3.352

Review 4.  Screening for gastrointestinal cancer: an epidemiological review.

Authors:  J Weil; M J Langman
Journal:  Gut       Date:  1991-02       Impact factor: 23.059

5.  Cost effectiveness of HemoQuant versus Hemoccult for colorectal cancer screening.

Authors:  A M Joseph; T W Crowson; E C Rich
Journal:  J Gen Intern Med       Date:  1988 Mar-Apr       Impact factor: 5.128

6.  Fecal occult blood testing for colorectal cancer in an ethnically diverse population.

Authors:  G A Glober; S Hundahl; J Stucke; M Choy
Journal:  West J Med       Date:  1994-10

7.  Screening and the costs of treating colorectal cancer.

Authors:  D K Whynes; A R Walker; J O Chamberlain; J D Hardcastle
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.